Experience over theory. Outcomes over frameworks
The Bio-nAbler Difference
Traditional consultants send junior analysts with frameworks. We send executives who have run the businesses, closed the deals, treated the patients, and built the relationships. The difference is measurable.
The numbers that prove it
$
0
B+
Deployed across 20 life science transactions
$
0
B+
P&L organizations led from Big Pharma to Branded Generics
0
%
Of all approved antibodies in use today rest on patents held by our team
0
+
Novel molecules taken into the clinic; 6 approved products including US$1B+ sellers
What you get with Bio-nAbler
vs. traditional consultant
| Capability | ✦ Bio-nAbler | Traditional Consultants |
|---|---|---|
|
P&L Ownership |
CEOs who’ve built and exited life science companies with US$500–800M+ valuations |
Partners overseeing junior teams with limited operational experience |
|
Scientific Innovation |
Inventors of world first technologies antibody platforms, world’s first ADCs |
MBAs applying standardized methodologies without sector depth |
|
Global Market Leadership |
Country MDs and Regional Presidents who’ve led Pfizer, UCB across 30+ countries |
Associates gathering market data without having lived the business |
|
Capital Deployed |
$2B+ invested across 20+ life science transactions with proven returns |
Spreadsheet analysis without having managed actual P&Ls |
|
Clinical Excellence |
Physicians who’ve treated patients, led 700 bed hospitals, pioneered therapies |
Generic recommendations without implementation experience |
|
Regulatory Mastery |
30 novel molecules into clinic; relationships with regulators built over decades |
Minimal relationships with regulators, KOLs, or industry executives |